Efeito sinérgico da oxitetraciclina em um tratamento combinado com Carboplatina na linhagem de células cancerígenas pulmonares MCF-7
DOI:
https://doi.org/10.11606/issn.1678-4456.bjvras.2022.191527Palavras-chave:
Carboplatina, Oxitetracilina, Células de câncer pulmonar (MCF-7), Ensaio in vitro, QuimioterapiaResumo
No tratamento do câncer de pulmão a resistência à quimioterapia é o maior problema no qual muitos tumores receptivos apresentam um rebote e desenvolvem a resistência. Quando oferecidas em combinações, as drogas anticancerígenas apresentam maior taxa de sucesso, reduzindo assim o risco de desenvolvimento de células cancerígenas resistentes. Contudo, a avaliação das terapias de combinação tem crescido muito rapidamente. Consequentemente, por reaproveitamento de tratamentos antigos, a descoberta de novos medicamentos adicionais que podem interagir sinergicamente com a quimioterapia que é considerada como auxílio médico na corrente busca à descoberta de novas medicações anticancerígenas ou estratégias terapêuticas. O propósito da presente pesquisa é aumentar a atividade anticancerígena da Carboplatina (CP) pelo incremento do efeito apoptótico de células de câncer pulmonar (MCF-7) em experimentos in vitro pela combinação com oxitetraciclina. Os resultados obtidos confirmaram elevado efeito sinérgico entre oxitetraciclina e Carboplatina em células MCF-7 representativas tratadas com Carboplatina, com e sem diferentes concentrações de oxitetraciclina (5% e 10% de IC50). A oxitetracilina que potencializou a ação da Carboplatina e/ou teve uma notável atividade relatada como um agente isolado. A pesquisa demonstrou a relação sinérgica entre oxitetraxiclina e Carboplatina nos ensaios de viabilidade. Surpreendentemente, os resultados obtidos sugeriram que as estratégias de tratamento inibidor podem aplicar uma janela terapêutica da Carboplatina com potencial para a terapia do câncer.
Downloads
Referências
Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AHH, Mohammed OY, Elhassan GO, Harguindey S, Reshkin SJ, Ibrahim ME, Rauch C. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15:71. https://doi.org/10.1186/s12935-015-0221-1. PMID: 26180516.
Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology: patient and health systems opportunities. Nat Rev Clin Oncol. 2015;12(12):732-42. https://doi.org/10.1038/nrclinonc.2015.169. PMid:26483297.
Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanotechnol. 2019;7(1):3-23. https://doi.org/10.2174/2211738507666190122111224. PMid:30666921.
Gray R, Bradley R, Braybrooke J, Liu Z, Peto R, Davies L, Dodwell D, McGale P, Pan H, Taylor C, Barlow W, Bliss J, Bruzzi P, Cameron D, Fountzilas G, Loibl S, Mackey J, Martin M, Del Mastro L, Möbus V, Nekljudova V, De Placido S, Swain S, Untch M, Pritchard KI, Bergh J, Norton L, Boddington C, Burrett J, Clarke M, Davies C, Duane F, Evans V, Gettins L, Godwin J, Hills R, James S, Liu H, MacKinnon E, Mannu G, McHugh T, Morris P, Read S, Wang Y, Wang Z, Fasching P, Harbeck N, Piedbois P, Gnant M, Steger G, Di Leo A, Dolci S, Francis P, Larsimont D, Nogaret JM, Philippson C, Piccart M, Linn S, Peer P, Tjan-Heijnen V, Vliek S, Mackey J, Slamon D, Bartlett J, Bramwell VH, Chen B, Chia S, Gelmon K, Goss P, Levine M, Parulekar W, Pater J, Rakovitch E, Shepherd L, Tu D, Whelan T, Berry D, Broadwater G, Cirrincione C, Muss H, Weiss R, Shan Y, Shao YF, Wang X, Xu B, Zhao D-B, Bartelink H, Bijker N, Bogaerts J, Cardoso F, Cufer T, Julien J-P, Poortmans P, Rutgers E, van de Velde C, Carrasco E, Segui MA, Blohmer JU, Costa S, Gerber B, Jackisch C, von Minckwitz G, Giuliano M, De Laurentiis M, Bamia C, Koliou G-A, Mavroudis D, A’Hern R, Ellis P, Kilburn L, Morden J, Yarnold J, Sadoon M, Tulusan AH, Anderson S, Bass G, Costantino J, Dignam J, Fisher B, Geyer C, Mamounas EP, Paik S, Redmond C, Wickerham DL, Venturini M, Bighin C, Pastorino S, Pronzato P, Sertoli MR, Foukakis T, Albain K, Arriagada R, Bergsten Nordström E, Boccardo F, Brain E, Carey L, Coates A, Coleman R, Correa C, Cuzick J, Davidson N, Dowsett M, Ewertz M, Forbes J, Gelber R, Goldhirsch A, Goodwin P, Hayes D, Hill C, Ingle J, Jagsi R, Janni W, Mukai H, Ohashi Y, Pierce L, Raina V, Ravdin P, Rea D, Regan M, Robertson J, Sparano J, Tutt A, Viale G, Wilcken N, Wolmark N, Wood W, Zambetti M. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393(10179):1440-52. https://doi.org/10.1016/S0140-6736(18)33137-4. PMid:30739743.
Hopkins, AL. Predicting promiscuity: a fossil record for exoplanets, News & Views. 2009; 462(112): 167-168.
Jawad MJ. Translational studies to support the use of pitavastatin as a cancer therapeutic [thesis]. Reino Unido: Keele University; 2020.
Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114:108800. https://doi.org/10.1016/j.biopha.2019.108800. PMid:30921705.
Jin KT, Lu ZB, Chen JY, Liu YY, Lan HR, Dong HY, Yang F, Zhao YY, Chen XY. Recent trends in nanocarrier-based targeted chemotherapy: selective delivery of anticancer drugs for effective lung, colon, cervical, and breast cancer treatment. J Nanomater. 2020;2020:1-14. https://doi.org/10.1155/2020/9184284.
Koltai T. Tetracyclines against cancer: a review In: RESEARCH Gate. Berlin: 2015. 29 p. https://doi.org/10.13140/RG.2.1.4097.1600.
Montemagno C, Pagès G. Metastatic heterogeneity of breast cancer: companion and theranostic approach in nuclear medicine. Cancers (Basel). 2020;12(4):821. https://doi.org/10.3390/cancers12040821. PMid:32235331.
Narayan RS, Molenaar P, Teng J, Cornelissen FMG, Roelofs I, Menezes R, Dik R, Lagerweij T, Broersma Y, Petersen N, Marin Soto JA, Brands E, van Kuiken P, Lecca MC, Lenos KJ, In ’t Veld SGJG, van Wieringen W, Lang FF, Sulman E, Verhaak R, Baumert BG, Stalpers LJA, Vermeulen L, Watts C, Bailey D, Slotman BJ, Versteeg R, Noske D, Sminia P, Tannous BA, Wurdinger T, Koster J, Westerman BA. A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities. Nat Commun. 2020;11:2935. https://doi.org/10.1038/s41467-020-16735-2. PMid:32523045.
Nowak-Sliwinska P, Scapozza L, Ruiz i Altaba A. Drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim Biophys Acta Rev Cancer. 2019;1871(2):434-54.
Rudrapal M, Khairnar JS, Jadhav AG. Drug repurposing (DR): an emerging approach in drug discovery. In: Badria FA, editor. Drug repurposing: hypothesis, molecular aspects and therapeutic applications. London: IntechOpen; 2020.
Sousa GFD, Wlodarczyk SR, Monteiro G. Carboplatin: molecular mechanisms of action associated with chemoresistance. Braz J Pharm Sci. 2014;50(4):693-701. https://doi.org/10.1590/S1984-82502014000400004.
Ulukaya E, Colakogullari M, Wood EJ. Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay. Chemotherapy. 2004;50(1):43-50. https://doi.org/10.1159/000077285. PMid:15084806.
Van den Bogert C, Kroon AM. Effects of oxytetracycline on in vivo proliferation and differentiation of erythroid and lymphoid cells in the rat. Clin Exp Immunol. 1982;50(2):327-35. PMid:7151329.
Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299-309. https://doi.org/10.1038/s41586-019-1730-1. PMid:31723286.
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141-60. PMid:34322663.
Yadav V, Talwar P. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: an underestimated truth. Biomed Pharmacother. 2019;111:934-46. https://doi.org/10.1016/j.biopha.2018.12.119. PMid:30841473.
Younus ZM. Design and fabrication of hydrogel scaffolds for osteochondral tissue regeneration [thesis]. Reino Unido: Keele University; 2019.
Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y, Huang C. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020;5(1):113. https://doi.org/10.1038/s41392-020-00213-8. PMid:32616710.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Brazilian Journal of Veterinary Research and Animal Science
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
O conteúdo do periódico está licenciado sob uma Licença Creative Commons BY-NC-SA (resumo da licença: https://creativecommons.org/licenses/by-nc-sa/4.0 | texto completo da licença: https://creativecommons.org/licenses/by-nc-sa/4.0/legalcode). Esta licença permite que outros remixem, adaptem e criem a partir do seu trabalho para fins não comerciais, desde que atribuam ao autor o devido crédito e que licenciem as novas criações sob termos idênticos.
